COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy

Verma, Yogesh Kumar; Verma, Ranjan; Tyagi, Nishant; Behl, Amanpreet; Kumar, Subodh; Gangenahalli, Gurudutta

doi:10.1007/s12015-020-10037-2

Cited by 19 publications

(18 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been suggested that AMPs that destroy the envelope glycoprotein can be used to stop or disrupt the life cycle of SARS-CoV-2 [ 287 ]. AMPs, which are found in the secretion of mesenchymal stem cells (MSCs), have antimicrobial properties, the ability to attenuate cytokine storms, and, therefore are an attractive approach to prevent the COVID-19 pandemic [ 288 ].…”

Section: Prediction and Development Of New Ampsmentioning

confidence: 99%

Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

Kurpe

Grishin

Surin

et al. 2020

IJMS

View full text Add to dashboard Cite

At present, much attention is paid to the use of antimicrobial peptides (AMPs) of natural and artificial origin to combat pathogens. AMPs have several points that determine their biological activity. We analyzed the structural properties of AMPs, as well as described their mechanism of action and impact on pathogenic bacteria and viruses. Recently published data on the development of new AMP drugs based on a combination of molecular design and genetic engineering approaches are presented. In this article, we have focused on information on the amyloidogenic properties of AMP. This review examines AMP development strategies from the perspective of the current high prevalence of antibiotic-resistant bacteria, and the potential prospects and challenges of using AMPs against infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

show abstract

Section: Prediction and Development Of New Ampsmentioning

confidence: 99%

Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

Kurpe

Grishin

Surin

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…The concept of cell therapy for the treatment of CF lung infection and inflammation is complex, particularly with the dynamic nature of the “drug” in the form of macrophages, hMSCs or both ( Hodges and Conlon, 2019 ). Fortunately, cell-based approaches have been described in other diseases such as alveolar proteinosis ( Suzuki et al, 2014 ), Niemen Pick disease ( Schuchman and Desnick, 2017 ) acute respiratory distress syndrome ( Horie et al, 2018 ), interstitial pulmonary fibrosis ( Bonfield and Caplan, 2010 ), bronchopulmonary dysplasia ( Cerny et al, 2008 ), rheumatoid arthritis ( Jorgensen, 2010 ) and others ( Lachmann et al, 2014 ; Morrison et al, 2017 ; Khoury et al, 2020 ; Verma et al, 2020 ). Bone marrow supplementation or hMSC therapy is not corrective longitudinally, but would enhance the capacity of patients to manage their own immune environment.…”

Section: Discussionmentioning

confidence: 99%

Enhancing Cystic Fibrosis Immune Regulation

et al. 2021

View full text Add to dashboard Cite

In cystic fibrosis (CF), sustained infection and exuberant inflammation results in debilitating and often fatal lung disease. Advancement in CF therapeutics has provided successful treatment regimens for a variety of clinical consequences in CF; however effective means to treat the pulmonary infection and inflammation continues to be problematic. Even with the successful development of small molecule cystic fibrosis transmembrane conductance regulator (CFTR) correctors and potentiators, there is only a modest effect on established infection and inflammation in CF patients. In the pursuit of therapeutics to treat inflammation, the conundrum to address is how to overcome the inflammatory response without jeopardizing the required immunity to manage pathogens and prevent infection. The key therapeutic would have the capacity to dull the inflammatory response, while sustaining the ability to manage infections. Advances in cell-based therapy have opened up the avenue for dynamic and versatile immune interventions that may support this requirement. Cell based therapy has the capacity to augment the patient’s own ability to manage their inflammatory status while at the same time sustaining anti-pathogen immunity. The studies highlighted in this manuscript outline the potential use of cell-based therapy for CF. The data demonstrate that 1) total bone marrow aspirates containing Cftr sufficient hematopoietic and mesenchymal stem cells (hMSCs) provide Cftr deficient mice >50% improvement in survival and improved management of infection and inflammation; 2) myeloid cells can provide sufficient Cftr to provide pre-clinical anti-inflammatory and antimicrobial benefit; 3) hMSCs provide significant improvement in survival and management of infection and inflammation in CF; 4) the combined interaction between macrophages and hMSCs can potentially enhance anti-inflammatory and antimicrobial support through manipulating PPARγ. These data support the development of optimized cell-based therapeutics to enhance CF patient’s own immune repertoire and capacity to maintain the balance between inflammation and pathogen management.

show abstract

“…The above review provides not only new knowledge about the molecular mechanisms of stem cells pro-regenerative action, clinical trials based on the use of MSCs with complete status ( Gov, 2020a , Gov, 2020b , Gov, 2020c , Gov, 2020d , Gov, 2020e ), but also summarizes the so far published knowledge on the use of stem cells in the treatment of SARS-CoV-2 infection ( Chen, 2020 , Khatri et al, 2018 , Waszak et al, 2012 , Li et al, 2016 , Li et al, 2020 , Chan et al, 2016 , Curley et al, 2017 , Lee et al, 2011 , Weiss and Dahlke, 2019 , Harrell et al, 2020 , Harrell et al, 2019 , Costela-Ruiz et al, 2020 , Tan et al, 2020 , Raza and Khan, 2020 , Krasnodembskaya et al, 2010 , Johnson et al, 2017 , Chow et al, 2020 , Sutton et al, 2016 , Cotter et al, 2012 , Van Linthout et al, 2011 , Thanunchai et al, 2015 , Wu et al, 2018 , ClinicalTrials.gov, 2020 , Connick et al, 2012 , Wilson et al, 2014 , Saleh et al, 2020 , Inamdar and Inamdar, 2013 , Walter et al, 2014 , Anjos-Afonso et al, 2004 , Shetty, 2020 , Liang et al, 2020 , Sengupta et al, 2020 , Hassanpour et al, 2020 , Akbari and Rezaie, 2020 , Tsuchiya et al, 2020 , Sánchez-Guijo et al, 2020 , Chen et al, 2020 , Foronjy et al, 2014 , Metcalfe et al, 2015 , Metcalfe, 2020 , Shu et al, 2020 , Irmak et al, 2020 , Bonifazi et al, 2020 , Lee, 2018 , Musiał-Wysocka et al, 2019 , Verma et al, 2020 , Lukomska et al, 2019 ), and also effects of SARS-CoV-2 infection on lung epithelial stem cells ( …”

Section: Discussionmentioning

confidence: 99%

“…The first side effects in the form of the disease may occur in the first month after the transplant ( Bonifazi et al, 2020 ). Further, clinical studies have shown that bone marrow MSCs with a potential profibrogenic potential can cause liver fibrosis ( Lee, 2018 , Musiał-Wysocka et al, 2019 , Verma et al, 2020 ). The available data also show the growth of neoplastic tumors such as lung cancer, breast cancer, prostate cancer, gastric cancer and colon cancer ( Lee, 2018 , Musiał-Wysocka et al, 2019 , Verma et al, 2020 ).…”

Section: Stem Cells Therapy For Covid-19mentioning

confidence: 99%

“…Further, clinical studies have shown that bone marrow MSCs with a potential profibrogenic potential can cause liver fibrosis ( Lee, 2018 , Musiał-Wysocka et al, 2019 , Verma et al, 2020 ). The available data also show the growth of neoplastic tumors such as lung cancer, breast cancer, prostate cancer, gastric cancer and colon cancer ( Lee, 2018 , Musiał-Wysocka et al, 2019 , Verma et al, 2020 ). Importantly, a serious infection such as interstitial pneumonia was reported in a clinical study using HSC and MSC compared to a control group of COVID-19 patients ( Verma et al, 2020 , Lukomska et al, 2019 ).…”

Section: Stem Cells Therapy For Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

Medical progress: Stem cells as a new therapeutic strategy for COVID-19

Musiał¹,

Górska‐Ponikowska²

2021

Stem Cell Research

View full text Add to dashboard Cite

Currently, the world is facing the SARS-CoV-2 pandemic, coronavirus of acute respiratory distress syndrome 2, causes of COVID-19. Coronaviruses are RNA single-stranded viruses that have an envelope. In addition, coronaviruses are classified into four subfamilies: alpha, beta, gamma and delta coronaviruses. The first of them, cause mildly symptomatic or asymptomatic infections, while beta-coronaviruses are responsible for severe diseases. SARS-CoV-2 belongs to the group of beta-coronaviruses. Current available therapies use corticosteroids to reduce inflammation, non-specific antiviral drugs or antibiotics in the treatment of secondary bacterial infections. In addition, therapies based on the use of hydroxychloroquine, chloroquine, remdesvir, ribavirin, interferon or lopinavir-ritonavir were also initially used. Mesenchemical stem cells (MSCs) are widely used in cell therapies, which include both basic research and clinical trials. Their exceptional effectiveness and safety have been confirmed and documented in many clinical studies, which include a number of inflammatory diseases involving the immune system – one of them is systemic lupus erythematosus. Available data indicate the ability to differentiate MSCs and their immunomodulatory effects. In addition, through interactions with immune cells, which include, but are not limited to, macrophages and dendritic cells, or paracrine secretion, MSCs are able to secrete a number of types of cytokines. MSCs are also characterized by tissue regeneration and regulation of inflammation. Due to their properties, researchers turned to determine whether MSC transplantation is able to improve the outcome of patients with COVID-19 viral pneumonia. The presented review provides not only new knowledge in the field of molecular mechanisms of pro-regenerative action of stem cells, but also have the potential to open up new prospects of action to improve lung tissue regeneration in COVID-19 patients. In addition, in review mentioned about clinical trials using MSCs with a complete status, as well as the latest discoveries in molecular biology, a platform model of pluripotent stem cells in the SARS-CoV-2 study on 3D animal models and nanoconjugates based on stem cells.

show abstract

COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy

Cited by 19 publications

References 120 publications

Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

Enhancing Cystic Fibrosis Immune Regulation

Medical progress: Stem cells as a new therapeutic strategy for COVID-19

Contact Info

Product

Resources

About